|  Help  |  About  |  Contact Us

Publication : Anti-Na<sup>+</sup>/K<sup>+</sup>-ATPase immunotherapy ameliorates α-synuclein pathology through activation of Na<sup>+</sup>/K<sup>+</sup>-ATPase α1-dependent autophagy.

First Author  Cao L Year  2021
Journal  Sci Adv Volume  7
Issue  5 PubMed ID  33571110
Mgi Jnum  J:314949 Mgi Id  MGI:6804012
Doi  10.1126/sciadv.abc5062 Citation  Cao L, et al. (2021) Anti-Na(+)/K(+)-ATPase immunotherapy ameliorates alpha-synuclein pathology through activation of Na(+)/K(+)-ATPase alpha1-dependent autophagy. Sci Adv 7(5)
abstractText  Na(+)/K(+)-ATPase (NKA) plays important roles in maintaining cellular homeostasis. Conversely, reduced NKA activity has been reported in aging and neurodegenerative diseases. However, little is known about the function of NKA in the pathogenesis of Parkinson's disease (PD). Here, we report that reduction of NKA activity in NKAalpha1(+/-) mice aggravates alpha-synuclein-induced pathology, including a reduction in tyrosine hydroxylase (TH) and deficits in behavioral tests for memory, learning, and motor function. To reverse this effect, we generated an NKA-stabilizing monoclonal antibody, DR5-12D, against the DR region ((897)DVEDSYGQQWTYEQR(911)) of the NKAalpha1 subunit. We demonstrate that DR5-12D can ameliorate alpha-synuclein-induced TH loss and behavioral deficits by accelerating alpha-synuclein degradation in neurons. The underlying mechanism for the beneficial effects of DR5-12D involves activation of NKAalpha1-dependent autophagy via increased AMPK/mTOR/ULK1 pathway signaling. Cumulatively, this work demonstrates that NKA activity is neuroprotective and that pharmacological activation of this pathway represents a new therapeutic strategy for PD.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Bio Entities

0 Expression